ORKA logo

ORKA Oruka Therapeutics, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$95.81
-1.76 (-1.80%)

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-1…

Market Cap: $6.50Bwww.orukatx.com

Price

No data yet.

Social Signal Score

54
5d
—
30d
53
7 mentions
—
60d
53
10 mentions
—
90d
55
13 mentions
—
news: 9 · rss: 4

Analyst Ratings

9 analysts
Buyconsensus
Strong Buy 0Buy 9Hold 0Sell 0Strong Sell 0
Avg price target$131.33+37.1%
Low $105Median $125High $180
Current Consensus

Revenue

$0.00
$0.00
Mar 2017Sep 2026

Analyst Estimates

FY2025
$-2.20
$-2.74–$-1.97
6 analysts
FY2026
$-2.55
$-2.78–$-2.31
7 analysts
FY2027
$-2.95
$-3.43–$-2.13
7 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Lawrence Otto Klein
Sector
Healthcare
Industry
Biotechnology
Employees
68
Beta
-0.39
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
115.16
www.orukatx.com